EP4702019A1 - Kristalliner lysinacetyltransferase 6a (kat6a)-inhibitor und verwendungen davon - Google Patents

Kristalliner lysinacetyltransferase 6a (kat6a)-inhibitor und verwendungen davon

Info

Publication number
EP4702019A1
EP4702019A1 EP24796103.0A EP24796103A EP4702019A1 EP 4702019 A1 EP4702019 A1 EP 4702019A1 EP 24796103 A EP24796103 A EP 24796103A EP 4702019 A1 EP4702019 A1 EP 4702019A1
Authority
EP
European Patent Office
Prior art keywords
compound
xrpd
crystalline form
pattern
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24796103.0A
Other languages
English (en)
French (fr)
Inventor
Yushu YIN
Xing LIANG
Xin Cheng
Luoheng QIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InSilico Medicine IP Ltd
Original Assignee
InSilico Medicine IP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InSilico Medicine IP Ltd filed Critical InSilico Medicine IP Ltd
Publication of EP4702019A1 publication Critical patent/EP4702019A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP24796103.0A 2023-04-25 2024-04-24 Kristalliner lysinacetyltransferase 6a (kat6a)-inhibitor und verwendungen davon Pending EP4702019A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023090649 2023-04-25
PCT/CN2024/089494 WO2024222725A1 (en) 2023-04-25 2024-04-24 Crystalline lysine acetyltransferase 6a (kat6a) inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
EP4702019A1 true EP4702019A1 (de) 2026-03-04

Family

ID=93255616

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24796103.0A Pending EP4702019A1 (de) 2023-04-25 2024-04-24 Kristalliner lysinacetyltransferase 6a (kat6a)-inhibitor und verwendungen davon

Country Status (7)

Country Link
EP (1) EP4702019A1 (de)
KR (1) KR20260016479A (de)
CN (1) CN121358730A (de)
AU (1) AU2024262206A1 (de)
IL (1) IL323883A (de)
MX (1) MX2025012350A (de)
WO (1) WO2024222725A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
CN114072394A (zh) * 2019-04-25 2022-02-18 拜耳股份公司 用于治疗癌症的酰基磺酰胺
PH12021553107A1 (en) * 2019-06-18 2022-08-01 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
WO2023088233A1 (en) * 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof

Also Published As

Publication number Publication date
IL323883A (en) 2025-12-01
AU2024262206A1 (en) 2025-12-04
WO2024222725A1 (en) 2024-10-31
CN121358730A (zh) 2026-01-16
KR20260016479A (ko) 2026-02-03
MX2025012350A (es) 2025-12-01

Similar Documents

Publication Publication Date Title
AU2018200168B2 (en) Salt form of a human histone methyltransferase ezh2 inhibitor
CN112888690B (zh) 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途
CN117769560A (zh) Egfr抑制剂的盐、晶型及其组合物和应用
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
EP3502103B1 (de) Kristallform, salztyp von substituiertem 2-hydro-pyrazol-derivat und herstellungsverfahren dafür
CN116768856A (zh) 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
AU2026201824A1 (en) Crystal form of imidazolinone derivative
CN108640910A (zh) 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
WO2024222725A1 (en) Crystalline lysine acetyltransferase 6a (kat6a) inhibitor and uses thereof
CN118076614A (zh) 一种egfr抑制剂的多晶型
CN121443610A (zh) 一种plk1激酶抑制剂的盐型、晶型及其制备方法和应用
EP3941472B1 (de) Crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
CN108299419B (zh) 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
CN107663207B (zh) 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
WO2024222893A1 (en) Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof
EP4596553A1 (de) Salz einer dioxanchinolinverbindung, kristallform davon, herstellungsverfahren dafür und verwendungen davon
CN116102545B (zh) 一种二芳基脲类PI3K/mTOR/HDAC多靶点抑制剂及其药物组合物和应用
WO2025167975A1 (en) Crystalline cyclin-dependent kinase (cdk) 12 and/or cdk13 inhibitor and uses thereof
HK40087682A (en) Hbr salt form for ezh2 inhibition
WO2023174300A1 (zh) Btk抑制剂的晶型及其酸式盐和其酸式盐的晶型
CN120607535A (zh) 一种kif18a抑制剂的可药用盐、晶型及其制备方法和应用
HK40026825B (en) Salt form for ezh2 inhibition
HK40026825A (en) Salt form for ezh2 inhibition
HK40050133B (en) Salts of substituted pyrrolopyrimidine cdk inhibitor, crystal and use thereof
HK40050133A (en) Salts of substituted pyrrolopyrimidine cdk inhibitor, crystal and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0010375_4702019/2026

Effective date: 20260319

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40132279

Country of ref document: HK